Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists
AJOB Neuroscience – February 05, 2024
Source: OpenAlex
Summary
Strong bipartisan support exists for supervised psilocybin use, a compelling finding from recent drug studies. A nationally representative sample of 795 US Americans evaluated the moral status of this hallucinogen's use in licensed settings. Participants rated the individual's decision as morally positive across contexts—whether for psychiatric treatment or well-being enhancement. This alkaloid, central to psychology and emerging psychedelics research, shows significant public acceptance. Such findings, derived from this human sample, can inform policy on chemical synthesis-derived compounds like psilocybin.
Abstract
The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.